Physicians

Chief, Division of Medical Oncology

Department / Division
Medicine / Medicine - Oncology

Address
DUMC 3476
Durham, NC 27710

Appointment Telephone
919-668-6688

Office Telephone
919-681-9509

Fax Telephone
919-681-5864

Training

• MD, Ohio State University College of Medicine, 1974

Residency

• Internal Medicine, Duke University Medical Center, 1974-1977
• Hematology/Oncology, Duke University Medical Center, 1977-1978, 1979-1981
• Medicine, Chief Resident, Duke University Medical Center, 1978-1979

Clinical Interests
Lung cancer (small-cell and non-small-cell), chemotherapy, hematopoietic growth factors, cancer clinical trials

Research Interests
1.  Lung cancer/new treatment approaches.
2.  Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3.  Cancer in the elderly and supportive care

Accomplishments

1.  Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to  reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2.  Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3.  Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Agennix
• Amgen, Inc.
• Celgene Corporation
• Chugai Pharmaceutical (Roche Holding)
• Eisai
• Eli Lilly & Co.
• Facet Biotech (Abbott)
• GTx, Inc.
• Genentech, Inc (Roche Holding)
• GlaxoSmithKline
• Hoffman LaRoche (Roche Holding)
• Johnson & Johnson
• Medtronic Inc.
• Ono Pharmaceuticals
• Quintiles

Representative Publications
4. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, Yang B-B, Gardner S, Miller-Messana MA, Shoemaker D, Garst J, Schwab G. Randomized, Dose- Escalation Study of SD/01 Compared with Daily Filgrastim in Patients Receiving Chemotherapy. J Clin Onc, 18(13), 2522-2528, 2000. (2000)

5. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade III JL, Winn RJ, Wozniak AJ, Somerfield MR for ASCO Growth Factors Expert Panel. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. J Clin Onc, 18 (20) 3558-3585, 2000. (2000)

3. Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, Menchaca D, Tomita D, Ozer H, Harker L. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. New Eng J Med; 336:404-409, 1997. (1997)

1. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction in the incidence of chemotherapy-induced febrile neutropenia in patients with small cell lung cancer by granulocyte colony-stimulating factor (R-metG-CSF). New Eng J of Med 1991; 325:164-171. (1991)

2. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction in the incidence of chemotherapy-induced febrile neutropenia in patients with small cell lung cancer by granulocyte colony-stimulating factor (R-metG-CSF). New Eng J of Med 1991; 325:164-171. (1991)